US Executive Compensation Proxy SEC Filings — April 27, 2026

27-04-2026

Coupang, Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 11, 2026 at 5:00 p.m. Pacific Time to elect eight director nominees (Proposal 1), ratify Samil PricewaterhouseCoopers as independent registered public accounting firm for the fiscal year ending December 31, 2026 (Proposal 2), and conduct a non-binding advisory vote to approve named executive officer compensation (Proposal 3). Stockholders of record as of the April 13, 2026 Record Date, holding 1,648,989,437 shares of Class A common stock (one vote per share) and 157,802,990 shares of Class B common stock (29 votes per share), are entitled to vote via internet, telephone, mail, or at the virtual meeting. No financial performance metrics or period comparisons are detailed in this proxy statement.

• ·Annual Meeting access via www.virtualshareholdermeeting.com/CPNG2026 using control number from Internet Notice or proxy card.
• ·Proxy materials, including 2025 Annual Report on Form 10-K, available at www.proxyvote.com; Internet Notice mailed on or about April 27, 2026.
• ·Voting deadline: 8:59 p.m. Pacific Time on June 10, 2026 for internet/telephone; no cumulative voting for directors.
• ·Headquarters: 720 Olive Way, Suite 600, Seattle, Washington 98101.

27-04-2026

MetaVia Inc. (MTVA) has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 8, 2026, at 10:00 a.m. ET, seeking approval for electing two Class I directors for three-year terms, ratifying BDO USA, P.C. as independent auditors for FY 2026, a discretionary reverse stock split of 1-for-5 to 1-for-22, amending the 2022 Equity Incentive Plan to add 200,000 shares, and authorizing adjournments for Proposals 3 and 4 if needed. As of the April 13, 2026 record date, 5,164,370 shares of Common Stock (par value $0.001) were outstanding, with a quorum requiring one-third of voting power present. The Board unanimously recommends voting FOR all proposals; no financial performance metrics or period comparisons are discussed.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/MTVA2026; requires 16-digit control number to vote remotely.
• ·Proxy voting deadline: 11:59 p.m. ET on June 7, 2026 via Internet.
• ·Proposal 1 (director election): plurality vote; Proposals 2, 4, 5: majority of voting power present; Proposal 3: majority of votes cast.
• ·Broker non-votes have no effect on any proposals; only Proposal 2 is routine (broker discretionary).

27-04-2026

Alliance Laundry Holdings Inc. has issued a proxy statement for its virtual Annual Meeting on June 11, 2026, seeking stockholder approval to elect three Class I directors—Michael D. Schoeb, Phyllis A. Knight, and Robert L. Verigan—to serve until the 2029 annual meeting; ratify Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026; approve on an advisory basis the frequency of future say-on-pay votes (Board recommends one year); and approve on an advisory basis the compensation of named executive officers. The Board consists of seven directors serving staggered three-year terms, with BDT Badger Holdings, LLC as the Principal Stockholder. As of the record date of April 16, 2026, 198,237,241 shares of common stock were outstanding.

• ·Annual Meeting is completely virtual via live webcast at www.virtualshareholdermeeting.com/ALH2026
• ·Record date for voting eligibility: April 16, 2026
• ·Board divided into three classes with staggered three-year terms per Fourth Amended and Restated Certificate of Incorporation
• ·Proxy materials and 2025 Annual Report available at http://www.proxyvote.com

27-04-2026

Ultra Clean Holdings, Inc. (UCTT) has filed its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders on May 22, 2026, at 12:30 p.m. PT, held virtually only. Key proposals include electing directors, ratifying PricewaterhouseCoopers LLP as independent auditors for fiscal 2026, an advisory vote on named executive officer compensation, and approvals of amendments and restatements to the stock incentive plan and employee stock purchase plan. The record date is March 27, 2026, with 44,825,713 shares of common stock outstanding.

• ·Annual meeting is virtual only at www.virtualshareholdermeeting.com/UCTT2026; physical attendance not permitted.
• ·Proxy materials available at http://materials.proxyvote.com.
• ·Board recommends voting FOR all proposals.

27-04-2026

RYTHM, Inc. filed a DEF 14A proxy statement for its virtual Annual Meeting of Stockholders on June 16, 2026, at 3:00 p.m. Central Time, proposing the election of seven directors (Benjamin Kovler, Max Holtzman, Timothy Mahoney, Peter Shapiro, Sanjay Tolia, Armon Vakili, and Krishnan Varier), ratification of GuzmanGray as independent auditor for the fiscal year ending December 31, 2026, and approval of an amendment to the 2022 Omnibus Equity Incentive Plan to increase available Common Stock by 115,000 shares. As of the record date of April 20, 2026, 2,149,128 shares of Common Stock were outstanding. No financial performance metrics or period-over-period comparisons are provided in the filing.

• ·Virtual meeting access: www.virtualshareholdermeeting.com/RYM2026
• ·Record date: April 20, 2026
• ·Proxy materials mailed on or about April 29, 2026
• ·Post-meeting reception at Garcia’s Chicago (1001 W Washington Blvd, Chicago, IL 60607) starting at 3:30 p.m. Central Time

27-04-2026

Velo3D, Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026, seeking approval to elect two Class II directors (Stefan Krause and new nominee Lily Mei), ratify Frank, Rimerman + Co. LLP as independent auditors for the year ending December 31, 2026, approve advisory votes on named executive officer compensation and say-on-pay frequency (recommending every 1 year), and amend the 2021 Equity Incentive Plan by increasing authorized common shares by 2,860,000. The record date is April 15, 2026. No financial performance metrics or period-over-period comparisons are discussed.

• ·Annual Meeting held virtually at www.virtualshareholdermeeting.com/VLD2026.
• ·Record Date: April 15, 2026.
• ·Filing Date: April 27, 2026.
• ·Board majority independent (3 out of 5 directors); all committees composed of independent directors.

27-04-2026

SkyWater Technology, Inc. (SKYT) has issued a proxy statement for its 2026 Annual Meeting of Stockholders, scheduled virtually on June 10, 2026, at 9:00 a.m. ET, to elect nine director nominees and ratify KPMG LLP as independent auditors for fiscal 2026. The meeting may not occur if the pending merger with IonQ, Inc., announced January 25, 2026, closes prior, as disclosed in a separate merger proxy filed March 31, 2026. Record date is April 13, 2026, with 49,157,448 shares of common stock outstanding.

• ·Annual Meeting held virtually only at www.virtualshareholdermeeting.com/SKYT2026; physical attendance not permitted.
• ·Fiscal year ends on the Sunday closest to the end of the twelfth calendar month; fiscal 2025 ended December 28, 2025.
• ·Board consists of nine directors, all standing for election annually.

27-04-2026

Green Thumb Industries Inc. (GTBIF) filed its DEF 14A proxy statement dated April 27, 2026, for the virtual annual and special shareholder meeting on June 16, 2026, at 2:00 p.m. CT, covering proposals to set the board at seven directors, elect directors, advisory approval of named executive officer compensation, re-appoint Baker Tilly US, LLP as auditors, and amend articles to modify automatic conversion of Super Voting Shares. The record date is April 20, 2026; no specific financial metrics or period-over-period comparisons are detailed in the provided filing excerpt, which focuses on governance and voting logistics.

• ·Voting deadline: 10:59 p.m. CT on June 12, 2026, or 48 hours before any adjournment.
• ·Post-meeting reception at Garcia’s Chicago (1001 W Washington Blvd, Chicago, IL 60607) at 3:30 p.m. CT on June 16, 2026.
• ·Proxy materials available at investors.gtigrows.com/2026proxy and 2026 Annual Report (including 10-K for year ended December 31, 2025) at investors.gtigrows.com/2026annualreport.

27-04-2026

Zomedica Corp.'s DEF 14A proxy statement discloses governance details, including Audit Committee meetings (4 times), Compensation Committee (3 times), and Nominating Committee (3 times) in 2025, with independent members overseeing key functions. Executive compensation for 2025 showed increases for CEO Larry Heaton (total $762,883 from $647,985 in 2024, +17.7%) and COO Tony Blair (total $390,151 from $367,782 in 2024, +6.1%), while other NEOs like Kevin Klass ($433,398 total) and Mike Zuehlke ($354,387 total) had single-year disclosures with no prior comparisons provided. The filing also profiles current executives and confirms policies like Code of Ethics, Clawback, and separated CEO/Chairman roles.

• ·Board separates Chairman (Mr. Rowe) and CEO (Larry Heaton) roles for balanced oversight.
• ·Audit Committee oversees financial reporting, internal controls, and pre-approves related-person transactions.
• ·Compensation Committee reviews executive comp policies, equity plans, and director compensation.
• ·Nominating Committee uses informal process for director candidates, considers shareholder recommendations.

27-04-2026

Everforth, Inc. (f/k/a ASGN Incorporated) has issued its 2026 Proxy Statement for the Annual Meeting on June 11, 2026, seeking stockholder approval for the election of three incumbent directors—Mark A. Frantz, Carol J. Lindstrom, and Arshad Matin—for three-year terms expiring in 2029, an advisory vote on named executive officer compensation for the year ended December 31, 2025, and ratification of Deloitte & Touche LLP as independent auditors for the year ending December 31, 2026. The Board size will decrease from 10 to 9 directors effective upon the retirement of Mr. Holman at the meeting's conclusion. The record date for voting eligibility is April 16, 2026.

• ·Annual Meeting location: The St. Regis San Francisco, 125 Third Street, San Francisco, CA 94103 at 9:00 a.m. Pacific Time.
• ·Board diversity: Three women directors, one Hispanic-American, one Asian-American.
• ·Voting methods: Telephone (1-800-652-VOTE), internet (www.investorvote.com/Everforth), mail, or in person.

27-04-2026

Orchid Island Capital, Inc., a REIT investing in Agency RMBS, filed its DEF 14A proxy statement for the 2026 Annual Meeting to elect six directors (four independent, one-third women), ratify BDO USA, P.C. as independent auditors for the fiscal year ending December 31, 2026, approve executive compensation on a non-binding basis, and recommend 'every one year' frequency for future say-on-pay votes. The Board held 17 meetings in 2025 with robust governance practices including stock ownership guidelines, prohibitions on pledging/hedging, insider trading policy, and compensation clawback. Record date for voting is April 9, 2026.

• ·Annual election of all directors under majority voting standard with resignation policy for those not receiving majority votes.
• ·Stockholders of record as of April 9, 2026 entitled to vote; each share has one vote.
• ·Corporate governance includes no poison pill, stockholder power to amend bylaws, and annual review of manager performance.

27-04-2026

Fortrea Holdings Inc. (FTRE) filed a DEF 14A proxy statement for its virtual Annual Meeting on June 9, 2026, seeking stockholder approval to elect Anshul Thakral, Peter M. Neupert, and William J. Sharbaugh as Class III directors until the 2028 Annual Meeting, ratify Deloitte & Touche LLP as independent auditors for FY 2026, and conduct an advisory 'Say-on-Pay' vote on named executive officer compensation. As of the April 15, 2026 record date, 94,584,730 shares of common stock were outstanding. The company, a spin-off from Labcorp effective June 30, 2023, employs approximately 14,300 people across 100 countries providing clinical development services.

• ·Annual Meeting time: 8:00 a.m. Eastern Time, virtual at www.virtualshareholdermeeting.com/FTRE2026
• ·Proxy materials and 2025 Annual Report available at www.proxyvote.com as of April 27, 2026
• ·Compensation disclosures reference PEOs including Thomas Pike (2023-2024), Anshul Thakral and Peter Neupert (2025), with Appendix A on non-GAAP metrics

27-04-2026

American Bitcoin Corp. (ABTC) has issued a proxy statement for its 2026 Annual Meeting of Stockholders on June 22, 2026, seeking approval to elect Asher Genoot as Class I director for a three-year term, ratify KPMG LLP as independent auditors for the fiscal year ending December 31, 2026, and authorize a reverse stock split of common stock at a board-determined ratio between 1-for-5 and 1-for-40. The record date is April 23, 2026, with 1,060,449,416 shares of common stock outstanding, including 328,224,513 Class A shares (1 vote each) and 732,224,903 Class B shares (10,000 votes each). No financial performance metrics or period comparisons are disclosed in the filing.

• ·Annual Meeting held virtually at www.virtualshareholdermeeting.com/ABTC2026
• ·Voting rights: Class A common stock (1 vote per share), Class B common stock (10,000 votes per share), Class C common stock (10 votes per share)
• ·Company formed via Hut 8 contribution on March 31, 2025, and Gryphon merger on September 3, 2025
• ·Proxy materials available at www.proxyvote.com

27-04-2026

Commercial Vehicle Group, Inc. (CVGI) filed its DEF 14A Proxy Statement on April 27, 2026, for the virtual Annual Meeting of Stockholders on May 14, 2026, seeking election of seven director nominees, approval of the Second Amended and Restated 2020 Equity Incentive Plan, an advisory vote to approve named executive officer compensation, and ratification of KPMG LLP as independent auditor for the fiscal year ending December 31, 2026. The statement includes executive compensation disclosures referencing Principal Executive Officers (PEOs) James R. Ray (2023-2025), Robert R. Griffin, and Harold Bevis (2021-2022). Record date is March 16, 2026.

• ·Virtual Annual Meeting: May 14, 2026, at 1:00 p.m. Eastern Time via www.virtualshareholdermeeting.com/CVGI2026 (16-digit control number required)
• ·Record Date: March 16, 2026
• ·Fiscal year references: 2025 (Jan 1 - Dec 31, 2025), 2024, 2023, 2022, 2021

27-04-2026

uniQure N.V. filed its DEF 14A definitive proxy statement on April 27, 2026, for the 2026 Annual General Meeting on June 10, 2026, at 9:00 a.m. CEST in Amsterdam, covering adoption of 2025 Dutch statutory annual accounts, discharge of Board liability, and reappointments of non-executive directors Madhavan Balachandran, Jack Kaye, and Leonard Post, Ph.D. The agenda also includes authorizations for share issuances and repurchases, appointment of KPMG Accountants N.V. as 2026 external auditors, advisory votes on executive compensation and frequency, and amendments to the 2014 Share Incentive Plan (increasing available shares) and Articles of Association.

• ·Record date: close of business CEST on May 13, 2026.
• ·Voting deadline: 9:59 p.m. CEST on June 9, 2026; attendance notice by 12:00 p.m. CEST on June 9, 2026 via investors@uniQure.com.
• ·Meeting location: Paasheuvelweg 25a, 1105 BP Amsterdam, the Netherlands.

27-04-2026

Miami International Holdings, Inc. (MIAX) filed a definitive proxy statement (DEF 14A) on April 27, 2026, for its 2026 Annual Meeting of Stockholders on June 16, 2026, at 8:00 a.m. ET via live webinar with no physical location. Shareholders will vote on electing 15 directors to serve until the 2027 annual meeting, approving on a non-binding advisory basis the compensation of named executive officers and the frequency of future say-on-pay votes (every 1, 2, or 3 years), and ratifying KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026.

• ·Record date for voting eligibility: April 20, 2026
• ·Virtual meeting access: www.virtualshareholdermeeting.com/MIAX2026 with 16-digit control number
• ·Proxy materials and Form 10-K for year ended December 31, 2025 available at http://ir.miaxglobal.com under 'SEC Filings'

27-04-2026

Bicara Therapeutics' DEF 14A proxy statement nominates Christopher Bowden, M.D. and Carolyn Ng, Ph.D. for election as Class II directors for three-year terms expiring in 2029, while Nils Lonberg, Ph.D. will not stand for re-election at the Annual Meeting, resulting in a board reduction from 10 to 9 members with no associated disputes. Michael Powell, Ph.D. will succeed Dr. Lonberg as chairperson of the nominating and corporate governance committee. The board comprises experienced leaders from biotech, pharma, and investment sectors.

• ·Class I directors (terms expire 2028): Ryan Cohlhepp, Pharm.D., Kiran Mazumdar-Shaw, Jake Simson, Ph.D.
• ·Class III directors (terms expire 2027): Kate Haviland, Claire Mazumdar, Ph.D., Michael Powell, Ph.D., Scott Robertson.
• ·Director ages as of April 15, 2026: Christopher Bowden (65), Carolyn Ng (42), Ryan Cohlhepp (49), Kiran Mazumdar-Shaw (73), Jake Simson (40), Nils Lonberg (70), Kate Haviland (50), Claire Mazumdar (36), Michael Powell (71), Scott Robertson (46).
• ·Annual Meeting voting results to be filed via Form 8-K within four business days.

27-04-2026

Keenova Therapeutics plc's DEF 14A Proxy Statement for the 2026 Annual General Meeting on June 2, 2026, highlights fiscal 2025 as a transformational year marked by the merger with Endo, Inc. (now Endo LP) and the spin-off of Par Health, Inc., repositioning the company as a U.S.-focused branded therapeutics firm targeting rare diseases. While emphasizing diversified portfolio growth in areas like rheumatology and neurology, it details extensive risks such as unrealized synergies, increased indebtedness, regulatory scrutiny, and potential litigation from transactions. Proposals include electing 9 directors, advisory votes on executive compensation and auditors, capital reduction, and Articles amendment.

• ·Record date: March 23, 2026
• ·Meeting location: Arthur Cox LLP, Ten Earlsfort Terrace, Dublin 2, D02 T380, Ireland
• ·9 director nominees proposed for election (Proposals 1(a) through 1(i))
• ·Fiscal year ended December 31, 2025; refers to Form 10-K for performance details

27-04-2026

Dogwood Therapeutics, Inc. (DWTX) filed a definitive proxy statement (DEF 14A) on April 27, 2026, for its 2026 Annual Meeting of Stockholders to be held virtually on June 16, 2026, at 10:00 a.m. ET. Key proposals include the election of seven director nominees, ratification of Forvis Mazars, LLP as independent auditors for the fiscal year ending December 31, 2026, approval of an amendment to increase authorized common and preferred shares, and advisory votes on say-on-frequency (recommended 1 year) and say-on-pay. As of the record date of April 21, 2026, 33,401,553 shares of common stock were outstanding.

• ·Annual Meeting held virtually only at https://edge.media-server.com/mmc/go/dwtx2026agm
• ·Proxy materials mailed on or about April 28, 2026
• ·Annual Report on Form 10-K for fiscal year ended December 31, 2025 available at https://ir.dwtx.com/events-presentations/meeting
• ·Board unanimously recommends FOR all proposals except 1 YEAR for say-on-frequency

27-04-2026

Rivian's 2026 Proxy Statement, filed April 27, 2026, seeks shareholder approval at the June 22, 2026 Annual Meeting for the election of two Class II Directors, Karen Boone and Aidan Gomez, to serve until the 2029 Annual Meeting. The Board of Directors consists of seven members divided into three staggered classes: Class I (Robert J. Scaringe, Peter Krawiec, Sanford Schwartz) until 2028, Class II (nominees) until 2029 if elected, and Class III (Jay Flatley, John Krafcik) until 2027. Nominees and continuing directors bring expertise in finance, AI, automotive, corporate development, and technology leadership.

• ·Annual Meeting scheduled for June 22, 2026.
• ·Board classes have staggered three-year terms per Restated Certificate of Incorporation.
• ·Directors may be removed only for cause by majority vote of outstanding voting stock.

27-04-2026

SharkNinja, Inc. filed its DEF 14A proxy statement for the 2026 Annual General Meeting on June 18, 2026, in hybrid format at its Needham, MA offices and virtually, seeking approval to re-appoint seven directors, ratify Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026, provide advisory approval of named executive officer compensation, select the frequency of future say-on-pay votes, and approve an amendment and restatement of its Memorandum and Articles of Association. The record date is April 22, 2026, with 141,568,925 Ordinary Shares outstanding entitled to vote. No financial performance metrics or period-over-period comparisons are detailed in the provided filing content.

• ·Ordinary Shares have par value of $0.0001
• ·Board recommends 'FOR' all proposals except 'ONE YEAR' for Proposal 4 frequency
• ·Ordinary resolutions require simple majority; Proposal 5 is special resolution
• ·Proxy materials available at www.proxyvote.com

27-04-2026

Yext, Inc. has issued its DEF 14A Proxy Statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026 at 8:30 a.m. ET, seeking approval to elect Daniel Englander and Andrew Sheehan as Class III directors until 2029, ratify Ernst & Young LLP as independent auditors for the fiscal year ending January 31, 2027, approve named executive officer compensation on an advisory basis, and approve the amended, restated, and extended 2016 Equity Incentive Plan. Stockholders of record as of April 13, 2026, representing 100,112,238 shares of common stock, are entitled to vote via internet, phone, or mail. Proxy materials were made available online around April 27, 2026, with the meeting accessible at www.virtualshareholdermeeting.com/YEXT2026.

• ·Annual Meeting record date: April 13, 2026
• ·Proxy materials notice mailed on or around April 27, 2026
• ·Fiscal year reference: ended January 31, 2026 (Annual Report), upcoming ending January 31, 2027

27-04-2026

Annexon, Inc.'s DEF 14A proxy statement discloses non-employee director compensation for FY 2025 ended December 31, 2025, with total compensation ranging from $162,215 (Bettina M. Cockroft, M.D.) to $475,989 (William (BJ) Jones, Jr.), consisting of cash fees ($43,500-$86,000) and option awards ($106,215-$432,489 grant date fair value). It details related-party transactions, including 2024 and 2025 pre-funded warrant purchases by Redmile Group, LLC (7M shares at $6.249/share and 3.75M at $2.599/share) and 2025 warrant amendments benefiting Redmile affiliates and Alerce Medical (affiliated with director Muneer A. Satter). The filing includes an appendix proposing to amend the certificate of incorporation to authorize 500M common shares and 5M preferred shares.

• ·Non-employee directors receive annual cash retainers: $40,000 base; $35,000 non-executive chair; Audit chair $20,000/chair $10,000; Compensation chair $12,000/chair $6,000; Nominating/Gov chair $10,000/chair $5,000; Science/Tech chair $12,000/chair $6,000.
• ·William (BJ) Jones, Jr. commenced Board service on January 9, 2025.
• ·Equity awards to executives priced February 27, 2025, two days before 2024 10-K filing.
• ·Related party transactions threshold: >$120,000 or 1% of avg total assets last two FYs.
• ·Company address: 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005.

27-04-2026

CareDx, Inc.'s DEF 14A proxy statement for the 2026 Annual Meeting on June 11, 2026 seeks stockholder approval for electing five directors, ratifying Deloitte & Touche LLP as auditors for FY 2026, advisory votes on executive compensation and frequency, and amending the 2024 Equity Incentive Plan to increase available shares. CEO John W. Hanna describes 2025 as a year of strong execution, with focus on strategy from October 2024 Investor Day and sustainable growth. No period-over-period financial metrics or declines are detailed in the provided content.

• ·Annual Meeting: Thursday, June 11, 2026 at 10:00 a.m. Pacific Time, virtually via http://www.virtualshareholdermeeting.com/CDNA2026
• ·Record Date: April 15, 2026
• ·Five directors to serve until 2027 annual meeting
• ·Fiscal year ending December 31, 2026 for auditor ratification
• ·Proxy materials mailed on or about April 27, 2026
• ·Company address: 8000 Marina Boulevard, 4th Floor, Brisbane, CA 94005
• ·Equity compensation plan information as of March 31, 2026

27-04-2026

Enliven Therapeutics' DEF 14A proxy statement outlines the annual meeting agenda, including the election of Richard Fair (President and CEO) and Lori Kunkel as Class III directors for three-year terms ending in 2029, while the board size decreases from 8 to 7 members following Richard Heyman's retirement. Six of the current eight directors are independent per Nasdaq standards, with the board divided into three classes with staggered terms. Stockholder proposals for the 2027 annual meeting must be received by December 28, 2026, and advance notices by March 11, 2027.

• ·Stockholder proposal inclusion deadline for 2027 annual meeting: December 28, 2026.
• ·Advance notice window for 2027 annual meeting proposals/nominations: not earlier than February 9, 2027, and not later than March 11, 2027.
• ·Director ages as of March 3, 2026: Richard Fair (57), Lori Kunkel (68), Mika Derynck (63), Rishi Gupta (48), Scott Garland (57), Rahul D. Ballal (48), Jake Bauer (47).

27-04-2026

Freshpet's 2026 proxy statement for the June 10 virtual annual meeting details surpassing $1B net sales in 2025 with positive free cash flow and market share gains, but notes a slowdown in net sales growth from 27% in 2024 to 13% amid consumer sentiment shifts and category slowdown. Stockholders are asked to elect 12 directors, ratify KPMG LLP as auditors for 2026, and approve say-on-pay on executive compensation. The record date is April 15, 2026.

• ·Annual meeting via webcast at www.virtualshareholdermeeting.com/FRPT2026; pre-registration required by June 9, 2026.
• ·Fiscal year ended December 31, 2025; proxy materials available at investors.freshpet.com.

27-04-2026

Savers Value Village, Inc. (SVV) filed its DEF 14A proxy statement for the 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026, at 9:00 A.M. PT, with a record date of April 13, 2026. Stockholders will vote on electing three Class III directors for three-year terms, ratifying KPMG LLP as independent auditors for the fiscal year ending January 2, 2027, and an advisory approval of named executive officer compensation. The document outlines board governance, including three standing committees (Audit, Compensation, Nominating, Governance & Sustainability) and a Repurchase Committee, with all directors attending at least 75% of meetings in fiscal 2025.

• ·Virtual meeting platform: www.virtualshareholdermeeting.com/SVV2026
• ·Audit Committee financial experts: Aina Konold and Susan O’Farrell
• ·Compensation Committee delegated authority to CEO and Chairperson for certain equity awards
• ·Stockholders Agreement with Ares Funds dated July 3, 2023, impacts director nominations
• ·All non-management directors meet in executive session regularly; independent directors annually

27-04-2026

Kyntra Bio, Inc. filed its DEF 14A proxy statement on April 27, 2026, for the 2026 Annual Meeting of Stockholders on June 12, 2026 (virtual), seeking to elect Michael Kauffman, M.D., Ph.D. as Class III director until the 2029 annual meeting, approve on an advisory basis the compensation of named executive officers, and ratify PricewaterhouseCoopers LLP as independent auditors for the year ending December 31, 2026. The record date is April 16, 2026. No financial performance metrics or period-over-period changes are detailed in the filing.

• ·Annual Meeting: June 12, 2026, 8:00 a.m. Pacific Time, virtual via www.virtualshareholdermeeting.com/KYNB2026
• ·Record Date: April 16, 2026
• ·Annual Report on Form 10-K for fiscal year ended December 31, 2025, filed March 16, 2026
• ·Proxy materials available at www.proxyvote.com

27-04-2026

Trupanion, Inc. (TRUP) filed its DEF 14A proxy statement dated April 27, 2026, for the 2026 Annual Meeting of Stockholders on June 10, 2026, at 9:00 a.m. PDT in Seattle, WA, with agenda items to elect nine directors, ratify Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and approve on a non-binding advisory basis the 2025 compensation of named executive officers. The record date is April 14, 2026, and stockholders must request admission tickets by May 14, 2026. The proxy references compensation data for Principal Executive Officers (PEOs) Darryl Rawlings and Margi Tooth across 2021-2025, including pay versus performance metrics.

• ·Annual Meeting location: 6100 4th Avenue South, Seattle, Washington 98108.
• ·Proxy materials available at https://investors.trupanion.com/financials/annual-reports/default.aspx and https://www.proxyvote.com.
• ·Includes sections on non-employee director compensation, executive compensation tables, pay versus performance (2021-2025), pay ratio, and equity compensation plan information.

27-04-2026

Cognition Therapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting of Stockholders on June 17, 2026, at 9:00 a.m. ET virtually at www.virtualshareholdermeeting.com/CGTX2026, to elect Class II directors Aaron Fletcher, Ph.D. and Lisa Ricciardi for three-year terms expiring in 2029 and to ratify Ernst & Young LLP as independent registered public accounting firm for 2026. The Board has 6 members including 5 independent directors and an independent Chairman. Recent clinical highlights include positive Phase 2 SHIMMER COG1201 results published for Dementia with Lewy Body showing strong responses across domains, launch of an expanded access program for DLB patients, and completion of enrollment in December 2025 for the Phase 2 START COG0203 study in 545 subjects with mild cognitive impairment and early Alzheimer’s disease, with topline results expected in 2027.

• ·Record Date: April 20, 2026
• ·Voting deadline (Internet/telephone): 11:59 p.m. ET on June 16, 2026
• ·Proxy materials available at www.proxyvote.com; paper 10-K requests to Chief Financial Officer at 2500 Westchester Ave., Purchase, New York 10577
• ·Director election by plurality vote; auditor ratification by majority of votes properly cast
• ·Quorum: one third of voting power of outstanding shares

27-04-2026

QuidelOrtho Corporation's DEF 14A proxy statement announces the 2026 Annual Meeting of Stockholders on June 16, 2026, at 8:30 a.m. PT, virtually via www.virtualshareholdermeeting.com/QDEL2026, with record date April 20, 2026. Stockholders will vote on electing 10 director nominees, advisory approval of Named Executive Officer compensation, and ratification of KPMG LLP as independent auditors for the fiscal year ending January 3, 2027. No financial performance metrics or period comparisons are provided in the filing.

• ·Record date: April 20, 2026
• ·Annual Meeting backup location if needed: 9975 Summers Ridge Road, San Diego, California 92121 at 9:30 a.m. PT
• ·Proxy materials available at www.proxyvote.com; requests for printed copies by June 2, 2026
• ·Board recommends FOR all proposals

27-04-2026

Ideal Power Inc. (IPWR) filed its DEF 14A proxy statement dated April 27, 2026, for its 2026 Annual Meeting, proposing the election of five directors to serve until the 2027 annual meeting, ratification of BPM LLP as independent auditors for the fiscal year ending December 31, 2026, advisory approval of named executive officer compensation, and approval of the Amended and Restated Ideal Power Inc. 2013 Equity Incentive Plan. As of the record date of April 24, 2026, there were 12,155,901 shares of common stock outstanding, with one vote per share. The virtual Annual Meeting will be held online at 10:00 a.m. Central Time, requiring registration by 11:59 p.m. EDT on June 2, 2026.

• ·Annual Meeting online check-in begins at 9:45 a.m. Central Time
• ·Stockholder list available for examination 10 days prior to Annual Meeting via website
• ·Compensation disclosures reference equity awards for Non-PEO/NEO and PEO members for fiscal years 2023, 2024, and 2025

27-04-2026

EyePoint Pharmaceuticals reported strong progress on DURAVYU in 2025, enrolling over 900 patients in Phase 3 wet AMD trials LUGANO and LUCIA with positive DSMC review in November 2025 and topline data expected mid-2026 for LUGANO. Following positive Phase 2 VERONA results for DME, the company initiated Phase 3 trials COMO and CAPRI in March 2026, targeting enrollment completion in Q3 2026. Ended 2025 with over $300 million in cash and investments, no debt, and runway into Q4 2027, while noting forward-looking risks including clinical, regulatory, and manufacturing uncertainties.

• ·cGMP manufacturing facility in Northbridge, Massachusetts, built to FDA and EMA standards
• ·No safety signals in DSMC review or prior trials

27-04-2026

Seres Therapeutics, Inc. (MCRB) filed a DEF 14A proxy statement for its virtual Annual Meeting on June 9, 2026, seeking approval to elect Stephen A. Berenson, Claire M. Fraser, Ph.D., and Richard N. Kender as Class II directors until 2029; ratify PricewaterhouseCoopers LLP as auditors for FY 2026; approve advisory say-on-pay for named executive officers; and amend the 2025 Incentive Award Plan to increase shares available for issuance. The record date is April 13, 2026, with 9,632,111 shares of common stock outstanding following a 1-for-20 reverse stock split in April 2025. The Board recommends voting FOR all proposals, with no financial performance metrics or period comparisons disclosed in the filing.

• ·Annual Meeting at 8:00 a.m. ET, completely virtual via www.virtualshareholdermeeting.com/MCRB2026 using 16-digit control number
• ·1-for-20 reverse stock split effected in April 2025; all share/per share numbers reflect this adjustment
• ·Proposal 5 allows adjournment if needed to solicit more proxies for Proposal 4

27-04-2026

Definium Therapeutics, Inc. has issued a proxy statement for its Annual General and Special Meeting on June 11, 2026, seeking shareholder approval for electing seven director nominees (Carol A. Vallone, Andreas Krebs, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Roger Adsett, and Robert Barrow), appointing KPMG LLP as auditor until 2027, and amending the 2025 Equity Incentive Plan to add 5,000,000 common shares. The company highlights strong governance practices, including 97.9% board meeting attendance and 100% committee attendance for fiscal 2025, an independent board (except CEO), and no poison pill or insider pledging. The record date is April 15, 2026, with proxy materials available online since April 27, 2026.

• ·Virtual meeting at www.virtualshareholdermeeting.com/DFTX2026; voting deadline June 10, 2026 at 11:59 p.m. ET.
• ·All directors independent except CEO; independent Chair and Vice Chair; annual election of all directors (no staggered board).
• ·Fiscal year ended December 31, 2025; 2025 Annual Report on Form 10-K available with proxy materials.

27-04-2026

Sionna Therapeutics, Inc. issued a DEF 14A proxy statement dated April 27, 2026, for its 2026 Annual Meeting on June 17, 2026, at 12:00 p.m. Eastern Time, to elect four Class II directors—H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D.—and ratify Deloitte & Touche LLP as independent auditors for the fiscal year ending December 31, 2026. The record date is April 21, 2026, with 45,142,330 shares of common stock outstanding. The meeting is virtual-only, requiring advance registration by June 16, 2026, at 11:59 p.m. Eastern Time.

• ·Initial public offering occurred in February 2025.
• ·Proxy materials and 2025 Annual Report available at https://materials.proxyvote.com/829401.
• ·Voting methods: online at www.proxyvote.com, telephone at 1-800-690-6903, or mail; deadlines June 16, 2026, 11:59 p.m. ET.
• ·Company address: 21 Hickory Drive, Suite 500, Waltham, MA 02451.

27-04-2026

Aclarion, Inc. filed a DEF 14A proxy statement for its 2026 Annual Meeting of Stockholders on June 4, 2026, with a record date of April 10, 2026, when 2,462,250 shares of common stock were outstanding, entitling record holders to one vote per share. Stockholders are voting on Proposal 1 (election of seven directors by plurality), Proposal 2 (ratification of independent auditor by majority vote), and Proposal 3 (Equity Plan Proposal by majority vote), with the meeting held in person at company offices in Broomfield, CO. The company retained Marrow Sodali LLC for proxy solicitation at a cost of $75,000.

• ·Quorum requires one-third of outstanding shares present in person or by proxy.
• ·Internet voting deadline: 11:59 p.m. ET on June 3, 2026; mail deadline prior to June 4, 2026.
• ·Proposals 1 and 3 are non-discretionary (broker non-votes have no effect); Proposal 2 is discretionary.

27-04-2026

Vital Farms, Inc. (VITL) filed its DEF 14A Proxy Statement on April 27, 2026, for the 2026 Annual Meeting of Stockholders on June 10, 2026 (virtual at www.proxydocs.com/VITL), with a record date of April 17, 2026. Stockholders are asked to vote on: (1) electing two director nominees for a three-year term, (2) ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 27, 2026, and (3) approving named executive officer compensation on an advisory basis. The proxy includes sections on corporate governance, board structure, commitment to impact, executive compensation discussion and analysis, pay versus performance disclosures, CEO pay ratio, and non-employee director compensation.

• ·Annual Meeting registration deadline: 5:00 p.m. CT on June 9, 2026.
• ·Stockholder list available for examination 10 days prior to meeting at company offices (email investors@vitalfarms.com).
• ·Company operates as a Delaware Public Benefit Corporation and Certified B Corporation.

27-04-2026

Sonida Senior Living, Inc. (SNDA) filed a DEF 14A proxy statement outlining Compensation Committee responsibilities, including review of executive compensation using peer data and third-party surveys, and engagement of independent consultant Meridian Compensation Partners, LLC for $107,000 in fees as of December 31, 2025. The filing details board leadership structure with Mr. Simanovsky as non-executive Chairman since March 2026, risk oversight by the Audit Committee, director nomination processes, and the Investor Rights Agreement with Conversant Fund A and Silk for board designations. No financial performance metrics or period-over-period comparisons are provided.

• ·Stockholder director recommendations must be received in writing by November 15th of a calendar year.
• ·Board separated Chairman and CEO roles in 2010; Mr. Johnson served as Chairman from November 2021 to March 2026.
• ·Conversant Fund A entitled to designate three board members and Chairman based on ownership; Silk entitled to one director.

27-04-2026

Xencor Inc's DEF 14A Proxy Statement for the June 16, 2026 annual meeting seeks stockholder approval for electing nine directors, ratifying KPMG LLP as auditors for FY 2026, amending the 2023 Equity Incentive Plan to add 4,000,000 shares (approx. 5.4% of outstanding shares), and an advisory vote on executive compensation. The company highlights pipeline progress with positive early clinical data for XmAb819 (25% partial response rate, 70% disease control rate in renal cell carcinoma) and other XmAb candidates in oncology and autoimmune diseases, ending 2025 with $610.8 million in cash, cash equivalents, and marketable debt securities. No declines or flat performance metrics were reported.

• ·Annual meeting location: 465 North Halstead Street, Suite 200, Pasadena, CA 91107 at 1:00 p.m. PT on June 16, 2026
• ·Record date for voting: April 17, 2026
• ·Nine director nominees to be elected for terms until next annual meeting

27-04-2026

EXLService Holdings, Inc. reported consolidated revenue of $2,087.7 million in fiscal 2025, up 13.6% YoY from $1,838.4 million in 2024, driven by strong growth in Healthcare and Life Sciences (+23.7%) and Banking, Capital Markets and Diversified Industries (+13.0%), though Insurance grew more modestly at 8.3%. Net income attributable to stockholders increased 26.6% to $251.0 million, with diluted EPS rising 28.0% to $1.54, and operating income margin expanded 70 basis points to 15.0%. The proxy statement seeks approval for director elections, auditor ratification, and say-on-pay at the June 16, 2026 annual meeting.

• ·Annual meeting scheduled for 9:00 AM ET on June 16, 2026, virtual format; record date April 23, 2026.
• ·96% Say-on-Pay approval for 2024 compensation at 2025 Annual Meeting.
• ·Cash and short-term investments $328.4M; debt $298.6M as of Dec 31, 2025.
• ·Operating income margin expanded 70 basis points to 15.0% in 2025.
• ·Board composition post-meeting: 7 directors, 6 independent; average age 65.4 years; 29% female; 29% diverse race/ethnicity.

27-04-2026

T-Mobile US, Inc.'s DEF 14A Proxy Statement for the 2026 Annual Meeting on June 16, 2026, proposes the election of 13 directors, ratification of Deloitte & Touche LLP as independent auditors for FY2026, and an advisory vote to approve 2025 named executive officer compensation, with the Board recommending FOR all items. The company highlights strong corporate governance practices including annual director elections, independent committee chairs, pay-for-performance compensation, and stockholder rights like special meetings. Deutsche Telekom holds voting control over 54.5% of outstanding common stock as of March 31, 2026, designating 10 board members.

• ·Annual Meeting: June 16, 2026 at 8:00 a.m. PDT, virtual at www.virtualshareholdermeeting.com/TMUS2026.
• ·Record date: April 17, 2026.
• ·Proxy materials mailed on or about April 27, 2026.
• ·Deutsche Telekom designates 10 of 13 Board members per Stockholders’ Agreement.

27-04-2026

Vor Biopharma Inc. has filed a definitive proxy statement for its 2026 Annual Meeting of Stockholders, to be held virtually on June 11, 2026, at 9:00 a.m. ET. Stockholders of record as of April 15, 2026, will vote on electing two Class II director nominees for three-year terms, approving the amendment and restatement of the Amended and Restated 2021 Equity Incentive Plan, and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Proxy materials are available online under the SEC's 'notice and access' rules, with notices mailed on or about April 27, 2026.

• ·Annual Meeting is online-only via live webcast at meetnow.global/MPC7QXV.
• ·Beneficial owners must register in advance by June 8, 2026, 5:00 p.m. ET with proof of legal proxy to attend and vote.
• ·2025 Annual Report available at www.investorvote.com/VOR.

27-04-2026

Sensei Biotherapeutics completed the acquisition of Faeth Therapeutics on February 17, 2026, issuing 10,497.0980 shares of Series B Preferred Stock convertible into 10,497,098 common shares, amid challenging biotech markets and failed prior financing efforts. Concurrently, a private placement issued 14,440.395 Series B shares convertible into 14,440,395 common shares. The proxy seeks approvals for Series B conversion (exceeding 20% of outstanding shares and resulting in change of control), increasing authorized common shares from 12,500,000 to 300,000,000, and new 2026 equity plans, with 1.5% of shares under support agreements but significant dilution risks ahead.

• ·Proposal 1 (Director Election): Plurality vote; 'Withhold' and broker non-votes have no effect.
• ·Proposal 2 (Auditor Ratification): Majority of shares present; routine matter with broker discretion.
• ·Proposals 3-6: Majority of votes cast; abstentions and broker non-votes have no effect.
• ·Proposal 7 (Adjournment): Majority of shares present.
• ·Acquisition closed February 17, 2026; private placement February 20, 2026.
• ·Proxy filed with SEC on March 30, 2026.

27-04-2026

SCYNEXIS INC (SCYX) is seeking stockholder approval via proxy for a reverse stock split at a Board-determined ratio of 1-for-5 to 1-for-10 to address Nasdaq minimum bid price noncompliance notified on June 20, 2025, with a compliance deadline of June 15, 2026, aiming to maintain listing, enhance marketability, liquidity, and employee attraction. However, risks include no assurance of sustained price increase, potential adverse market perception, reduced liquidity from fewer shares, odd-lot issues, and ongoing delisting possibility. As of April 1, 2026, equity plans have 3,519,408 options, 2,711,600 RSUs, and 1,020,999 PRSUs (at max) outstanding, which would be proportionately adjusted.

• ·Par value per share of common stock remains $0.001 post-split.
• ·Board has discretion to abandon the reverse stock split or select ratio based on market conditions, trading price, volume, and holder impact.
• ·No change to authorized preferred stock or periodic reporting under Exchange Act.
• ·Future share issuances could dilute existing stockholders' ownership without preemptive rights.

27-04-2026

Krispy Kreme, Inc.'s DEF 14A proxy statement filed April 27, 2026, discloses FY2025 executive compensation for named executive officers (NEOs), with CEO Joshua Charlesworth's total at $3,693,795, up 47% YoY from FY2024's $2,510,455 driven by higher stock and option awards, but down 77% from FY2023's $11,260,174 due to significantly lower stock grants and no non-equity incentive payout (vs. $511k in FY2024 and $874k in FY2023). Other NEO totals varied, with CFO Raphael Duvivier at $2,811,282 (up from $1,486,626 in FY2024) but former CFO Jeremiah Ashukian's at $1,125,089 amid his departure, and no non-equity incentives for most in FY2025. No recovery of excess incentive compensation was required under the Clawback Policy after a minor redeemable noncontrolling interests classification error was corrected.

• ·All equity awards granted under the Omnibus Plan.
• ·FY2025 annual incentive targets: CEO $1M, CFO Duvivier $560k (threshold $280k, max $1.12M).
• ·Sign-on awards for Jeremiah Ashukian in FY2023: $675k bonus, $1.5M RSUs, $2M options.
• ·Nicola Steele FY2025 non-equity incentive of $23,242 from prior Australia/NZ plan.

27-04-2026

Target Corporation's 2026 Proxy Statement announces Michael Fiddelke as the new CEO following a deliberate Board-led succession process, highlighting his extensive experience in key leadership roles. The Board nominates 12 directors for election, including new independent directors Stephen Bratspies and John Hoke, III, while three directors—Douglas Baker, Grace Puma, and Donald Knauss—will not seek re-election or retire per tenure policies. Shareholders are asked to ratify Ernst & Young LLP as auditors, approve executive compensation on an advisory basis, and approve the Amended and Restated 2020 Long-Term Incentive Plan.

• ·Annual Meeting: June 10, 2026 at 12:00 p.m. Central Daylight Time, virtually at virtualshareholdermeeting.com/TGT2026
• ·Record Date: April 13, 2026
• ·Voting deadlines: Registered/Beneficial Owners by 11:59 p.m. EDT June 9, 2026; 401(k) Plan by 6:00 a.m. EDT June 8, 2026

27-04-2026

Vivid Seats Inc. will hold its 2026 Annual Meeting of Stockholders virtually on June 9, 2026 at 9:00 a.m. CT to elect Craig Dixon and Adam Stewart as Class II directors until the 2029 Annual Meeting and to ratify, on a non-binding basis, the appointment of Deloitte & Touche LLP as independent registered public accounting firm for 2026. Stockholders of record as of the April 17, 2026 record date, when 10,987,411 shares of Class A common stock were outstanding, can vote online, by telephone, or by mail. Proxy materials, including the 2025 Form 10-K, are available at www.proxyvote.com.

• ·Annual Meeting accessible via www.virtualshareholdermeeting.com/SEAT2026
• ·Voting facilities available until 10:59 p.m. CT on June 8, 2026 for internet and telephone
• ·Proposal 1 (director election) is non-routine; Proposal 2 (auditor ratification) is routine, potentially allowing broker non-votes on Proposal 1

27-04-2026

Standard BioTools Inc. (LAB) filed its definitive DEF 14A proxy statement on April 27, 2026, for the virtual 2026 Annual Meeting of Stockholders on June 17, 2026, at 11:30 a.m. ET. Key proposals include electing three Class I directors to terms expiring in 2029, an advisory vote to approve named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditors for the fiscal year ending December 31, 2026, approval of the 2026 Equity Incentive Plan, and an amendment to the Amended and Restated 2017 Employee Stock Purchase Plan increasing available shares by 1,200,000. The board recommends approval of all items; record date is April 24, 2026.

• ·Record Date: April 24, 2026
• ·Virtual meeting platform opens: 10:45 a.m. ET on June 17, 2026
• ·2025 Annual Report on Form 10-K filed with SEC on March 16, 2025
• ·Company address: 50 Milk Street, 10th Floor, Boston, Massachusetts 02109
• ·Proxy materials available at www.proxyvote.com and www.sec.gov

27-04-2026

Seritage Growth Properties' DEF 14A proxy statement for the 2026 annual meeting discloses 2025 compensation actually paid (CAP) to principal executive officer Andrea L. Olshan at $6,355,955, slightly below the reported summary compensation table total of $6,386,016 due to a negative equity award adjustment of $(30,061) from changes in fair value of prior-year awards vested in 2025. Average CAP for Non-PEO NEOs was $1,945,620, down marginally from the average reported total of $1,951,814 owing to a $(6,194) equity adjustment. Shareholders will vote on electing six trustees, ratifying Deloitte & Touche LLP as auditors for 2026, and an advisory vote approving executive compensation.

• ·Record date for shareholders: April 13, 2026
• ·Proxy materials first made available: April 27, 2026
• ·Trustees nominated for election until 2027 annual meeting: John T. McClain, Adam Metz, Talya Nevo-Hacohen, Mitchell Sabshon, Allison L. Thrush, Mark Wilsmann